Sequoia China led a $43m Series B round in BoomRay Pharmaceuticals.

Synopsis

Sequoia China, a venture capital firm, led a $43m Series B round in BoomRay Pharmaceuticals, a biotech company.

Principals

Boomray Pharmaceuticals

Hongshan (ex-sequoia Capital China)

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Bidder Team (1)

neil shen

Founding Partner at HONGSHAN (EX-SEQUOIA CAPITAL CHINA)

Investor

bidder

Deals

£ 15.88 B

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy